At the conclusion of this activity, learners should be able to:
- Understand the basis and clinical relevance of PD-L1 immunohistochemical scoring in non-small cell lung carcinoma
- Become familiar with LAG-3 as a biomarker and immunotherapy target in non-small cell lung carcinoma
Add to calendar:
Session date:
12/10/2021 - 12:00pm to 1:00pm EST
Room Number:
Zoom Meeting
Speaker Name:
Daniel Shepherd, MD, PhD, Massachusetts General Hospital